Bulgarian Property Developments
STRONG BUYTrading at a significant discount to net assets and poised to pay out a 19p exceptional dividend, Bulgarian Property Developments (BPD) looks decidedly undervalued.
BPD has promised to pay the dividend as part of its rejection of a takeover by speculator Joe Lewis. Joint chief executive Ivo Hesmondhalgh says the payment has now ‘got court approval’ and will be paid by early July.
Net assets, valued independently by Colliers, stood at 75p per share in December (at a rate of £1 to €1.36) and could rise to 90p if planning permission is granted on a site in central Sofia. Hesmondhalgh aims to increase 'density' at the site from the currently approved 135,000 sq m to 250,000 sq m, and says permission should be granted ‘by the end of the year’.
As part of the defence against the Lewis bid – which cost the company £680,000 and meant it reported a loss of £594,000 for the six months to December – a second dividend of 13p was promised, from asset realisation. Hesmondhalgh says this won’t necessarily be from a sale of the Sofia site, ‘as we might enter into a joint venture for it’.
Elsewhere within the portfolio, there were ‘minor disappointments’ at two sites, but all in all, things are progressing well and Hesmondhalgh says, ‘Bulgaria is not that affected by the credit crunch; there weren’t many mortgages or credit cards. All three of our banks will lend to us, although at slightly higher rates.’
Taking the 19p dividend into account, investors buying at the current 55.5p will effectively be paying only 36.5p once the dividend is subtracted.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £60.07m
PE Forecast: n/a
Share price: 55.5p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
